🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

Recruitingn/aAges 18 Years - anyAllNiguarda Hospital
NCT03601702 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria * Signed Informed Consent Form * Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1 * ASPECTS ≥ 6 * Mismatch or good collaterals showed at MR or multiphasic CTA or pCT * Groin Puncture performed within 12 hours from symptom onset * Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment Exclusion criteria * Informed consent not given * Extracranial or tandem occlusion
💊

What it tests

  • Mechanical thrombectomy with EmboTrap ® II Device
📍

Where

1 site
ASST GOM Niguarda
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy